A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safetyof 445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508delMutation and a Gating or Residual Function Mutation (F/G and F/RF Ge

Billings, Joanne L (PI)

Pulmonary, Allergy, Critical Care and Sleep Medicine
Administration (RIO)

Project: Research project

Description

A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of 445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Gating or Residual Function Mutation (F/G and F/RF Ge

Status	Finished
Effective start/end date	5/23/19 → 1/1/21

Funding

VERTEX PHARMACEUTICALS INCORPORATED

A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safetyof 445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508delMutation and a Gating or Residual Function Mutation (F/G and F/RF Ge

Project Details

Description

Funding

Fingerprint